Literature DB >> 12830325

In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.

Teréz Márián1, Gábor Szabó, Katalin Goda, Henrietta Nagy, Nóra Szincsák, István Juhász, László Galuska, László Balkay, Pál Mikecz, Lajos Trón, Zoltán Krasznai.   

Abstract

P-glycoprotein (Pgp) is an ABC (ATP binding cassette) transporter that is often overexpressed in tumours, contributing significantly to their multidrug resistance. In this study, we explored whether the radiotracers used in tumour diagnostics can be used for in vivo visualisation of Pgp-related multidrug resistance. We also examined the effects of different Pgp modulators on the accumulation of these radioligands in tumours with or without Pgp expression. In a SCID BC-17 mouse model, cells of the drug-sensitive KB-3-1 (MDR(-)) and the KB-V1 Pgp-expressing (MDR(+)) human epidermoid carcinoma cell lines were inoculated to yield tumours in opposite flanks. For in vivo scintigraphic (biodistribution) and positron emission tomography (PET) examinations, the mice were injected with technetium-99m hexakis-2-methoxybutylisonitrile ((99m)Tc-MIBI), carbon-11 labelled methionine and fluorine-18 fluoro-2-deoxy- d-glucose ((18)FDG). For validation, in vitro cell studies with (99m)Tc-MIBI,( 99m)Tc-tetrofosmin, [(11)C]methionine and (18)FDG were carried out using a gamma counter. The expression and function of the MDR product were proved by immunohistochemistry and spectrofluorimetry. (99m)Tc-MIBI uptake was significantly lower in KB-V1 cells as compared with KB-3-1-derived tumours in vivo (Pgp(+)/Pgp(-) =0.61+/-0.13; P<0.01) and cells in vitro (Pgp(+)/Pgp(-) =0.08+/-0.01; P<0.001).()Cyclosporin A reversed (99m)Tc-MIBI uptake in the Pgp+ cells, while verapamil failed to modify it. (18)FDG uptake was significantly higher in KB-V1 tumours (Pgp(+)/Pgp(-) =1.36+/-0.05; P<0.01) and cells (Pgp(+)/Pgp(- )=1.52+/-0.12; P<0.001). Whereas cyclosporin A eliminated the difference between FDG uptake in MDR(+) and MDR(-) cell lines, verapamil significantly increased it. When the animals were treated with verapamil, the ratio of (99m)Tc-MIBI uptake in the MDR(+) tumours to that in the MDR(-) tumours decreased to 0.38+/-0.05 ( P<0.01), while the ratio of (18)FDG uptake increased to 2.1+/-0.3 ( P<0.001). There were no significant differences in the [(11)C]methionine uptake in the MDR(+) and MDR(-) tumours and cell lines, nor was [(11)C]methionine accumulation modified by cyclosporin A. Parallel administration of (18)FDG and (99m)Tc-MIBI combined with verapamil treatment seems to be a good candidate as a non-invasive marker for the diagnosis of MDR-related Pgp expression in tumours.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830325     DOI: 10.1007/s00259-003-1204-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

Review 1.  The human ATP-binding cassette (ABC) transporter superfamily.

Authors:  M Dean; Y Hamon; G Chimini
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

2.  Characterization of P-glycoprotein transport and inhibition in vivo.

Authors:  E Barbarics; J F Kronauge; D Cohen; A Davison; A G Jones; J M Croop
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

3.  Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state.

Authors:  P Lu; R Liu; F J Sharom
Journal:  Eur J Biochem       Date:  2001-03

4.  Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

Authors:  B J Trock; F Leonessa; R Clarke
Journal:  J Natl Cancer Inst       Date:  1997-07-02       Impact factor: 13.506

5.  Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer.

Authors:  L Kostakoglu; P Kiratli; S Ruacan; M Hayran; S Emri; E L Ergün; C F Bekdik
Journal:  J Nucl Med       Date:  1998-02       Impact factor: 10.057

Review 6.  Visualization of multidrug resistance in vivo.

Authors:  N H Hendrikse; E J Franssen; W T van der Graaf; W Vaalburg; E G de Vries
Journal:  Eur J Nucl Med       Date:  1999-03

7.  Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents.

Authors:  H J Broxterman; H M Pinedo; C M Kuiper; G J Schuurhuis; J Lankelma
Journal:  FEBS Lett       Date:  1989-04-24       Impact factor: 4.124

8.  Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer.

Authors:  J Zhou; K Higashi; Y Ueda; Y Kodama; D Guo; F Jisaki; A Sakurai; T Takegami; S Katsuda; I Yamamoto
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

9.  Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.

Authors:  V V Rao; M L Chiu; J F Kronauge; D Piwnica-Worms
Journal:  J Nucl Med       Date:  1994-03       Impact factor: 10.057

10.  MDR1 causes resistance to the antitumour drug miltefosine.

Authors:  M Rybczynska; R Liu; P Lu; F J Sharom; E Steinfels; A D Pietro; M Spitaler; H Grunicke; J Hofmann
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

View more
  14 in total

1.  Breast scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

Review 2.  Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.

Authors:  Ana F Brito; Mónica Mendes; Ana M Abrantes; José G Tralhão; Maria F Botelho
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

3.  A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.

Authors:  Thomas Wanek; Claudia Kuntner; Jens P Bankstahl; Marion Bankstahl; Johann Stanek; Michael Sauberer; Severin Mairinger; Sabine Strommer; Volker Wacheck; Wolfgang Löscher; Thomas Erker; Markus Müller; Oliver Langer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-10-08       Impact factor: 9.236

4.  Evaluation of morphine effect on tumour angiogenesis in mouse breast tumour model, EATC.

Authors:  Funda Ustun; Gülay Durmus-Altun; Semsi Altaner; Nermin Tuncbilek; Cem Uzal; Sakir Berkarda
Journal:  Med Oncol       Date:  2010-06-22       Impact factor: 3.064

5.  A systemic review of PET and biology in lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Noriaki Sunaga; Tamotsu Ishizuka; Kimihiro Shimizu; Nobuyuki Yamamoto
Journal:  Am J Transl Res       Date:  2011-07-27       Impact factor: 4.060

6.  Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.

Authors:  Nicolas Tournier; Wadad Saba; Sébastien Goutal; Philippe Gervais; Héric Valette; Jean-Michel Scherrmann; Michel Bottlaender; Salvatore Cisternino
Journal:  AAPS J       Date:  2015-02-26       Impact factor: 4.009

Review 7.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

Review 8.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance.

Authors:  Shuang Liu; Young-Seung Kim; Shizhen Zhai; Jiyun Shi; Guihua Hou
Journal:  Bioconjug Chem       Date:  2009-04       Impact factor: 4.774

10.  Bromocriptine enhances the uptake of (99m)Tc-MIBI in patients with hepatocellular carcinoma.

Authors:  Xiangting Chai; Qiaoyu Liu; Wenyu Shao; Feng Zhang; Xuehao Wang; Hai Wang
Journal:  J Biomed Res       Date:  2012-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.